Treatment of chronic hepatitis C with different genotypes

Hepatitis C Virus Disease: Immunobiology and Clinical Applications

Volumn , Issue , 2008, Pages 130-147

  Fung, James ^a   Lai, Ching Lung ^a   Yuen, Man Fung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865512097     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-71376-2_7     Document Type: Chapter

References (82)

1. Adinolfi, L. E., Gambardella, M., Andreana, A., Tripodi, M. F., Utili, R., Ruggiero, G. (2001). Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology, 33(6):1358-1364.
2. Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., Margolis, H. S. (1999). The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine, 341(8):556-562.
3. Bjoro, K., Bell, H., Hellum, K. B., Skaug, K., Raknerud, N., Sandvei, P., Doskeland, B., Maeland, A., Lund-Tonnesen, S., Myrvang, B. (2002). Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scandinavian Journal of Gastroenterology, 37(2):226-232.
4. Bruno, S., Silini, E., Crosignani, A., Borzio, F., Leandro, G., Bono, F., Asti, M., Rossi, S., Larghi, A., Cerino, A., Podda, M., Mondelli, M. U. (1997). Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology, 25(3):754-758.
5. Bruno, S., Camma, C., Di Marco, V., Rumi, M., Vinci, M., Camozzi, M., Rebucci, C., Di Bona, D., Colombo, M., Craxi, A., Mondelli, M. U., Pinzello, G. (2004). Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. Journal of Hepatology, 41(3):474-481.
6. Bukh, J., Miller, R. H., Purcell, R. H. (1995). Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Seminars in Liver Disease, 15:41-63.
7. Buti, M., Sanchez-Avila, F., Lurie, Y., Stalgis, C., Valdes, A., Martell, M., Esteban, R. (2002). Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology, 35(4):930-936.
8. Chamberlain, R. W., Adams, N., Saeed, A. A., Simmonds, P., Elliott, R. M. (1997). Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. Journal of General Virology, 78:1341-1347.
9. Choo, Q. L., Richman, K. H., Han, J. H., Berger, K., Lee, C., Dong, C., Gallegos, C., Coit, D., Medina-Selby, R., Barr, P. J., Weiner, P. J., Bradley, D. W., Kuo, G., Houghton, M. (1991). Genetic organization and diversity of the hepatitis C virus. Proceedings of the National Academy of Sciences USA, 88:2451-2455.
10. Chung, R. T., Monto, A., Dienstag, J. L., Kaplan, L. M. (1999). Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus. Journal of Medical Virology, 58(4):353-358.
11. Dalgard, O., Bjoro, K., Block Hellum, K., Myrvang, B., Ritland, S., Skaug, K., Raknerud, N., Bell, H. (2004). Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology, 40(6):1260-1265.
12. Delwaide, J., Gerard, C., Reenaers, C., Vaira, D., Bastens, B., Bataille, C., Servais, B., Maes, B., Belaiche, J., Hepatotropes GL; Groupe Liegeois d'Etudes des Virus Hepatotropes (GLEVE) (2005). Hepatitis C virus genotype 5 in southern Belgium: epidemiological characteristics and response to therapy. Digestive Diseases and Sciences, 50(12):2348-2351.
13. Dev, A. T., McCaw, R., Sundararajan, V., Bowden, S., Sievert, W. (2002). Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology, 36(5):1259-1265.
14. El-Zayadi, A., Simmonds, P., Dabbous, H., Prescott, L., Selim, O., Ahdy, A. (1996). Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. Journal of Viral Hepatology, 3:261-264.
15. El-Zayadi, A., Selim, O., Haddad, S., Simmonds, P., Hamdy, H., Badran, H. M., Shawky, S. (1999). Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Italian Journal of Gastroenterology and Hepatology, 31(6):472-475.
16. Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Izumi, N., Marumo, F., Sato, C. (1995). Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. Journal of Clinical Investigation, 96(1):224-230.
17. Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Ogura, Y., Izumi, N., Marumo, F., Sato, C. (1996). Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. New England Journal of Medicine, 334(2):77-81.
18. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., Yu, J. (2002). Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347(13):975-982.
19. Gale, M., Jr., Blakely, C. M., Kwieciszewski, B., Tan, S. L., Dossett, M., Tang, N. M., Korth, M. J., Polyak, S. J., Gretch, D. R., Katze, M. G. (1998). Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Molecular and Cellular Biology, 18(9):5208-5218.
20. Gaudy, C., Lambele, M., Moreau, A., Veillon, P., Lunel, F., Goudeau, A. (2005). Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome. Journal of Clinical Microbiology, 43(2):750-754.
21. Hadziyannis, S. J., Sette, H., Jr., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H. Jr., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P. J., Lin, A., Ackrill, A. M.; PEGASYS International Study Group (2004). Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140(5):346-355.
22. Hasan, F., Asker, H., Al-Khaldi, J., Siddique, I., Al-Ajmi, M., Owaid, S., Varghese, R., Al-Nakib, B. Peginterferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. American Journal of Gastroenterology, 99(9):1733-1737.
23. Henquell, C., Cartau, C., Abergel, A., Laurichesse, H., Regagnon, C., De Champú, C., Baillo, J. L., Peigue-Lafeuille, H. (2004) High prevalence of hepatitis C virus type 5 in central France evidenced by a prospective study from 1996 to 2002. Journal of Clinical Microbiology, 42(7):3030-3035.
24. Hui, C. K., Yuen, M. F., Sablon, E., Chan, A. O., Wong, B. C., Lai, C. L. (2003). Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. Journal of Infectious Disease, 187(7):1071-1074.
25. Ikeda, K., Kobayashi, M., Someya, T., Saitoh, S., Tsubota, A., Akuta, N., Suzuki, F., Suzuki, Y., Arase, Y., Kumada, H. (2002). Influence of hepatitis C virus subtype on hepatocellular carcinogenesis: a multivariate analysis of a retrospective cohort of 593 patients with cirrhosis. Intervirology, 45(2):71-78.
26. Kamal, S. M., El Tawil, A. A., Nakano, T., He, Q., Rasenack, J., Hakam, S. A., Saleh, W. A., Ismail, A., Aziz, A. A., Madwar, M. A. (2005). Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut, 54(6):858-866.
27. Khorsi, H., Castelain, S., Wyseur, A., Izopet, J., Canva, V., Rombout, A., Capron, D., Capron, J. P., Lunel, F., Stuyver, L., Duverlie, G. (1997). Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alpha therapy in French patients. Journal of Hepatology, 27(1):72-77.
28. Khuroo, M. S., Khuroo, M. S., Dahab, S. T. (2004). Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Alimentary Pharmacology and Therapeutics, 20(9):931-938.
29. Koshy, A., Marcellin, P., Martinot, M., Madda, J. P. (2000). Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis. Liver, 20:335-339.
30. Koshy, A., Madda, J. P., Marcellin, P., Martinot, M. (2002). Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. Journal of Clinical Gastroenterology, 35:82-85.
31. Kumar, D., Farrell, G. C., Fung, C., George, J. (2002). Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology, 36(5):1266-1272.
32. Layden, T. J., Layden, J. E., Reddy, K. R., Levy-Drummer, R. S., Poulakos, J., Neumann, A. U. (2002). Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. Journal of Viral Hepatology, 9(5):334-339.
33. Legrand-Abravanel, F., Sandres-Saune, K., Barange, K., Alric, L., Moreau, J., Desmorat, P., Vinel, J. P., Izopet, J. (2004). Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. Journal of Infectious Diseases, 189(8):1397-1400.
34. Lonardo, A., Loria, P., Adinolfi, L. E., Carulli, N., Ruggiero, G. (2006). Hepatitis C and steatosis: a reappraisal. Journal of Viral Hepatology, 13(2):73-80.
35. Mangia, A., Santoro, R., Minerva, N., Ricci, G. L., Carretta, V., Persico, M., Vinelli, F., Scotto, G., Bacca, D., Annese, M., Romano, M., Zechini, F., Sogari, F., Spirito, F., Andriulli, A. (2005). Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. New England Journal of Medicine, 352(25):2609-2617.
36. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M., Albrecht, J. K. (2001). Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358(9286):958-965.
37. McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M. H., Cort, S., Albrecht, J. K. (1998). Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine, 339(21):1485-1492.
38. McKechnie, V. M., Mills, P. R., McCruden, E. A. (2000). The NS5a gene of hepatitis C virus in patients treated with interferon-alpha. Journal of Medical Virology, 60(4):367-378.
39. Moriya, K., Fujie, H., Shintani, Y., Yotsuyanagi, H., Tsutsumi, T., Ishibashi, K., Matsuura, Y., Kimura, S., Miyamura, T., Koike, K. (1997). Hepatitis C virus core protein induces steatosis in transgenic mice. Journal of General Virology, 78:1527-1531.
40. Naoumov, N. V., Chokshi, S., Metivier, E., Maertens, G., Johnson, P. J., Williams, R. (1997). Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis. Journal Of Hepatology. Aug; 27(2):331-6.
41. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C:2002 - June 10-12. (2002). National Institute of Health Consensus State-of-the-Science Statements. June 10-12; 19(3):1-46.
42. Neumann, A. U., Lam, N. P., Dahari, H., Davidian, M., Wiley, T. E., Mika, B. P., Perelson, A. S., Layden, T. J. (2000) Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. Journal of Infectious Diseases, 182(1):28-35.
43. Pascu, M., Martus, P., Hohne, M., Wiedenmann, B., Hopf, U., Schreier, E., Berg, T. (2004). Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut, 53(9):1345-1351.
44. Paterson, M., Laxton, C. D., Thomas, H. C., Ackrill, A. M., Foster, G. R. (1999). Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology, 117(5):1187-1197.
45. Pawlotsky, J. M. (2003). The nature of interferon-alpha resistance in hepatitis C virus infection. Current Opinion in Infectious Diseases, 16(6):587-592.
46. Pawlotsky, J. M., Taskiris, L., Roudot-Thoraval, F., Pellet, C., Stuyver, L., Duval, J., Dhumeaux, D. (1995). Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. Journal of Infectious Diseases, 171:1607-1610.
47. Perez, R., Jimenez, M., Crespo, J., Diago, M., Enriquez, J., Vaquero, P., Sola, R., Olcoz, J. L., Romero, M., Salmeron, J., Blanco, M. I., Ona, M., Melon, S., Rodrigo, L. (2003). Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C. Journal of Viral Hepatitis, 10(6):437-445.
48. Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., Albrecht, J. (1998). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet, 352(9138):1426-1432.
49. Poynard, T., Ratziu, V., McHutchison, J., Manns, M., Goodman, Z., Zeuzem, S., Younossi, Z., Albrecht, J. (2003). Effect of treatment with peginterferon or interferon alpha-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology, 38(1):75-85.
50. Prescott, L. E., Simmonds, P., Lai, C. L., Chan, N. K., Pike, I., Yap, P. L., Lin, C. K. (1996). Detection and clinical features of hepatitis C virus type 6 infections in blood donors from Hong Kong. Journal of Medical Virology, 50:168-175.
51. Quer, J., Murillo, P., Martell, M., Gómez, J., Esteban, J. I., Esteban, R. & Guardia, J. (2004). Subtype mutations in the envelope 2 region including phosphorylation homology domain of hepatitis C virus do not predict effectiveness of antiviral therapy. Journal of Viral Hepatitis, 11:45-54.
52. Reid, A. E., Koziel, M. J., Aiza, I., Jeffers, L., Reddy, R., Schiff, E., Lau, J. Y., Dienstag, J. L., Liang, T. J. (1999) Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States. American Journal of Gastroenterology, 94(6):1619-1926
53. Remy, A. J., Verdier, E., Perney, P., Ducos, J., Blanc, P., Blanc, F., Larrey, D. (1998). Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country (Letter). Journal of Hepatology, 29:169.
54. Robertson, B., Myers, G., Howard, C., Brettin, T., Bukh, J., Gaschen, B., Gojobori, T., Maertens, G., Mizokami, M., Nainan, O., Netesov, S., Nishioka, K., Shin, I. T., Simmonds, P., Smith, D., Stuyver, L., Weiner, A. (1998). Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Archives in Virology, 143:2493-2503.
55. Rubbia-Brandt, L., Quadri, R., Abid, K., Giostra, E., Male, P. J., Mentha, G., Spahr, L., Zarski, J. P., Borisch, B., Hadengue, A., Negro, F. (2000). Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. Journal of Hepatology, 33(1):106-115.
56. Saito, T., Ito, T., Ishiko, H., Yonaha, M., Morikawa, K., Miyokawa, A., Mitamura, K. (2003). Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b. American Journal of Gastroenterology, 98:1377-1383.
57. Schinkel, J., Spoon, W. J., Kroes, A. C. (2004). Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions. Antiviral Therapy, 9(2):275-286.
58. Shi, S. T., Polyak, S. J., Tu, H., Taylor, D. R., Gretch, D. R., Lai, M. M. (2002). Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Vi ro l o g y, 292(2):198-210.
59. Shobokshi, O. A., Serebour, F. E., Skakni, L., Al Khalifa, M. (2003). Combination therapy of peginterferon alfa-2a and ribavirin significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia. Hepatology, 38:996A.
60. Simmonds, P., Alberti, A., Alter, H. J., Bonino, F., Bradley, D. W., Brechot, C., Brouwer, J. T., Chan, S. W., Chayama, K., Chen, D. S. (1994). A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology, 19(5):1321-1324.
61. Simmonds, P., Bukh, J., Combet, C., Deleage, G., Enomoto, N., Feinstone, S., Halfon, P., Inchauspe, G., Kuiken, C., Maertens, G., Mizokami, M., Murphy, D. G., Okamoto, H., Pawlotsky, J. M., Penin, F., Sablon, E., Shin-I, T., Stuyver, L. J., Thiel, H. J., Viazov, S., Weiner, A. J., Widell, A. (2005). Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology, 42(4):962-973.
62. Smuts, H. E., Kannemeyer, J. (1995). Genotyping of hepatitis C virus in South Africa. Journal of Clinical Microbiology, 33:1679-1681.
63. Squadrito, G., Leone, F., Sartori, M., Nalpas, B., Berthelot, P., Raimondo, G., Pol, S., Brechot, C. (1997). Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alpha. Gastroenterology, 113(2):567-572.
64. Tanaka, H., Tsukuma, H., Yamano, H., Okubo, Y., Inoue, A., Kasahara, A., Hayashi, N. (1998). Hepatitis C virus 1b (II) infection and development of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma: a case-control study in Japan. Journal of Epidemiology, 8(4):244-249.
65. Taylor, D. R., Shi, S. T., Romano, P. R., Barber, G. N., Lai, M. M. C. (1999). Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science, 285:107-109.
66. Thakeb, F. A. I., Omar, M. M., El Awady, M. M., Isshak, S. Y. (2003). Randomized controlled trial of peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus genotype 4 among Egyptian patients. Abstract 37, Proceedings of the 54th Annual Meeting of the AASLD, Boston, MA, October 24-28.
67. Tokita, H., Okamoto, H., Iizuka, H., Kishimoto, J., Tsuda, F., Lesmana, L. A., Miyakawa, Y., Mayumi, M. (1996). Hepatitis C virus variants from Jakarta, Indonesia, classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. Journal of General Virology, 77:293-301.
68. Tokita, H., Okamoto, H., Tsuda, F., Song, P., Nakata, S., Chosa, T., Iizuka, H., Mishiro, S., Miyakawa, Y., Mayumi, M. (1994). Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. Proceedings of the National Academy of Sciences USA, 91:11022-11026.
69. Van Vlierberghe, H., Leroux-Roels, G., Adler, M., Bourgeois, N., Nevens, F., Horsmans, Y., Brouwer, J., Colle, I., Delwaide, J., Brenard, R., Bastens, B., Henrion, J., De Vries, R. A., De Galocsy, C., Michielsen, P., Robaeys, G., Bruckers, L. (2003). Daily induction combination treatment with alpha 2b interferon and ribavirin or standard combination treatment in naive chronic hepatitis C patients. A multicentre randomized controlled trial. Journal of Viral Hepatology, 10(6):460-466.
70. Von Wagner, M., Huber, M., Berg, T., Hinrichsen, H., Rasenack, J., Heintges, T., Bergk, A., Bernsmeier, C., Haussinger, D., Herrmann, E., Zeuzem, S. (2005). Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology, 129(2):522-527.
71. Watanabe, H., Nagayama, K., Enomoto, N., Itakura, J., Tanabe, Y., Sato, C., Izumi, N., Watanabe, M. (2003). Amino acid substitutions in PKR-eIF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy. Hepatology Research, 26:268-274.
72. Wong, D. A., Tong, L. K., Lim, W. (1998). High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong. European Journal of Epidemiology, 14:421-426.
73. World Health Organization. Hepatitis C. Factsheet No 164 (2000). http://www.who.int/mediacentre/factsheets.
74. Zein, N. N., Rakela, J., Krawitt, E. L., Reddy, K. R., Tominaga, T., Persing, D. H. (1996a). Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Annals of Internal Medicine, 125(8):634-639.
75. Zein, N. N., Poterucha, J. J., Gross J, B, Jr., Wiesner, R. H., Therneau, T. M., Gossard, A. A., Wendt, N. K., Mitchell, P. S., Germer, J. J., Persing, D. H. (1996b). Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1b. American Journal of Gastroenterology, 91:2560-2562.
76. Zhang, Y. Y., Lok, A. S., Chan, D. T., Widell, A. (1995). Greater diversity of hepatitis C virus genotypes found in Hong Kong than in mainland China. Journal of Clinical Microbiology, 33:2931-2934.
77. Zeuzem, S., Lee, J. H., Roth, W. K. (1997). Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alpha. Hepatology, 25(3):740-744.
78. Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M. Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., Hoffman, J., Brunda, M. J. (2000). Peginterferon alfa-2a in patients with chronic hepatitis C. New England Journal of Medicine, 343(23):1666-1672.
79. Zeuzem, S., Herrmann, E., Lee, J. H., Fricke, J., Neumann, A. U., Modi, M., Colucci, G., Roth, W. K. (2001). Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology, 120(6):1438-1447.
80. Zeuzem, S., Hultcrantz, R., Bourliere, M., Goeser, T., Marcellin, P., Sanchez-Tapias, J., Sarrazin, C., Harvey, J., Brass, C., Albrecht, J. (2004). Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. Journal of Hepatology, 40(6):993-939.
81. Erratum in Journal of Hepatology, 42(3):434.
82. Zylberberg, H., Chaix, M. L., Brechot, C. (2000). Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-A (Letter). Annals of Internal Medicine, 132:845-846.